Method for evaluating the efficacy of a composition in reducing the effects of cancer therapeutics on skin
An epidermal tridimensional model exhibiting differentiating keratinocytes in a reconstituted stratum corneum model is disclosed. The model, which contains a cancer therapeutic at an amount effective to simulate chronic drug exposure, can be used to evaluate the potential of cancer therapeutics to produce skin related side effects. The method can also be used to evaluate the efficacy of a composition in reducing the effects of cancer therapeutics on skin.
1. An in vitro or ex vivo epidermal tridimensional model comprising:
a first reconstructed human epidermis, the first reconstructed human epidermis representing a first stage of maturity;
a second reconstructed human epidermis, the second reconstructed human epidermis representing a second stage of maturity different than the first stage of maturity;
calcium;
an air liquid interface;
a cancer therapeutic that stimulates chronic drug exposure; and
a means to measure trans-epidermal water loss rate at each of the first reconstructed human epidermis and the second reconstructed human epidermis,
wherein the model functionally reproduces barrier compromise due to the chronic drug exposure to the cancer therapeutic.
2. A method to test a cancer therapeutic to determine if the cancer therapeutic produces skin related side effects, comprising comparing the measured trans-epidermal water loss rate of the cancer therapeutic in claim 1 to a control; wherein an increase in trans-epidermal water loss rate of the cancer therapeutic as compared to the control indicates skin barrier impairment.
3. A method to test a composition to determine if the composition can prevent the effect the cancer therapeutic has on skin barrier structure and function, measuring the trans-epidermal water loss rate in the model of claim 1 ; introducing the composition to said model of claim 1 ; measuring trans-epidermal water loss rate with the composition present; comparing trans-epidermal water loss rate with the composition present to trans-epidermal water loss without the composition present; wherein a decrease in trans-epidermal water loss rate indicates that the composition can prevent the effect the cancer therapeutic has on skin barrier structure and function.
4. The method of claim 1 , wherein the measured trans-epidermal water loss rate is measured using Tewitro® TW 24, at 33° C.
5. The method of claim 4 , wherein measurements to measure the trans-epidermal water loss rate are taken after 1 hour stabilization.
6. The method of claim 1 , wherein the cancer therapeutic is selected from the group consisting of Sunitinib; Sorafenib; Gefitinib; Erlotinib; Afatinib; Lapatinib; Dacomitinib; Osimertinib; and Osimertinib.
7. The method of claim 1 , wherein the cancer therapeutic is afatinib.